Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:KIN Kindred Biosciences (KIN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Kindred Biosciences Stock (NASDAQ:KIN) 30 days 90 days 365 days Advanced Chart Ad Behind the MarketsDemocrats Sold Out the American Dream - Are you ready?There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters."Click here to see exactly what you need to do >>> Get Kindred Biosciences alerts:Sign Up Key Stats Today's Range$9.24▼$9.2650-Day Range$9.08▼$9.2552-Week Range$3.46▼$9.28Volume178,496 shsAverage Volume840,890 shsMarket Capitalization$420.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.Read More… Democrats Sold Out the American Dream - Are you ready? (Ad)There's a massive housing crisis looming, and nobody on Main Street knows it yet... The Democrats sold out the American Dream - and now, millions of Americans are locked out of the housing market, forced to become "permanent renters."Click here to see exactly what you need to do >>> Kindred Biosciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks17th Percentile Overall ScoreKIN MarketRank™: Kindred Biosciences scored higher than 17% of companies evaluated by MarketBeat, and ranked 892nd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Kindred Biosciences. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Kindred Biosciences are expected to grow in the coming year, from ($0.71) to ($0.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kindred Biosciences is -8.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKindred Biosciences has a P/B Ratio of 5.29. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for KIN. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKindred Biosciences does not currently pay a dividend.Dividend GrowthKindred Biosciences does not have a long track record of dividend growth. Sustainability and ESG3.8 / 5Environmental Score-1.96 Short InterestThere is no current short interest data available for KIN. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for KIN on MarketBeat in the last 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kindred Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders13.69% of the stock of Kindred Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.89% of the stock of Kindred Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kindred Biosciences' insider trading history. Receive KIN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kindred Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address KIN Stock News HeadlinesWhy Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom ChiAugust 19, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”April 23, 2024 | msn.comWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.November 22, 2024 | InvestorPlace (Ad)Tory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceMarch 22, 2024 | mirror.co.ukKindred Hospital East GreensboroFebruary 23, 2024 | health.usnews.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | reuters.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetJanuary 22, 2024 | markets.businessinsider.comSee More Headlines KIN Stock Analysis - Frequently Asked Questions How were Kindred Biosciences' earnings last quarter? Kindred Biosciences, Inc. (NASDAQ:KIN) posted its quarterly earnings data on Thursday, August, 5th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.04. The biopharmaceutical company earned $3.54 million during the quarter, compared to analysts' expectations of $8.12 million. Kindred Biosciences had a negative net margin of 529.26% and a negative trailing twelve-month return on equity of 54.19%. What other stocks do shareholders of Kindred Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kindred Biosciences investors own include CorMedix (CRMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), bluebird bio (BLUE), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Meta Platforms (META). Company Calendar Last Earnings8/05/2021Today11/21/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:KIN CUSIPN/A CIK1561743 Webkindredbio.com Phone(650) 701-7901FaxN/AEmployees63Year Founded2013Profitability EPS (Most Recent Fiscal Year)($0.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,800,000.00 Net Margins-529.26% Pretax MarginN/A Return on Equity-54.19% Return on Assets-39.76% Debt Debt-to-Equity Ratio0.19 Current Ratio7.02 Quick Ratio7.02 Sales & Book Value Annual Sales$42.16 million Price / Sales9.97 Cash FlowN/A Price / Cash FlowN/A Book Value$1.75 per share Price / Book5.29Miscellaneous Outstanding Shares45,462,000Free FloatN/AMarket Cap$420.52 million OptionableOptionable Beta1.30 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report This page (NASDAQ:KIN) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | SponsoredNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kindred Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kindred Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
